Xtant Medical acquired the nanOss production operations from RTI Surgical for $2 million in cash plus contingent payments.
Under the terms of the purchase agreement, Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business, and assumed from RTI the lease for the nanOss production facility located in Greenville, North Carolina. Contingent payments are based on future sales of next-generation nanOss products. Xtant previously acquired nanOss distribution rights and nanOss intellectual property with the acquisition of Surgalign’s assets related to its biologics and spinal fixation business in August 2023.
“nanOss is an important part of our total orthobiologics offering, and having full control over this product line enables us to begin the process of reviving and growing it,” said Sean Browne, Chief Executive Officer of Xtant Medical. “This deal satisfies each element of our acquisition criteria and positions us to improve our manufacturing capabilities, capacity and cash flows.”
Xtant Medical acquired the nanOss production operations from RTI Surgical for $2 million in cash plus contingent payments.
Under the terms of the purchase agreement, Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business, and assumed from RTI the lease for the nanOss production facility...
Xtant Medical acquired the nanOss production operations from RTI Surgical for $2 million in cash plus contingent payments.
Under the terms of the purchase agreement, Xtant acquired certain assets, including equipment and inventory, used in RTI’s synthetic bone graft business, and assumed from RTI the lease for the nanOss production facility located in Greenville, North Carolina. Contingent payments are based on future sales of next-generation nanOss products. Xtant previously acquired nanOss distribution rights and nanOss intellectual property with the acquisition of Surgalign’s assets related to its biologics and spinal fixation business in August 2023.
“nanOss is an important part of our total orthobiologics offering, and having full control over this product line enables us to begin the process of reviving and growing it,” said Sean Browne, Chief Executive Officer of Xtant Medical. “This deal satisfies each element of our acquisition criteria and positions us to improve our manufacturing capabilities, capacity and cash flows.”
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
